Crowdsourced High-Risk Classifiers for Multiple Myeloma Patients Commonly Identify PHF19 As a Robust Progression Biomarker
Year: 2019
Type: conference-abstract
Source: Blood
Authors: Michael J Mason, Carolina D. Schinke, Christine Eng, Fadi Towfic, Fred Gruber, Brian S. White, Yi Cui, Bailiang Li, Thomas Yu, William S. Dalton, Hartmut Goldschmidt, Herve Avet-Loiseau, Mehmet Samur, Maria Ortiz, Matthew Trotter, Boris Hayete, Andrew Dervan, Erin Flynt, Hongyue Dai, Douglas Bassett, Pieter Sonneveld, Kenneth H. Shain, Nikhil C. Munshi, Daniel Auclair, Dirk Hose, Gareth Morgan, Jonathan Göke, Brian A Walker, Anjan Thakurta, Justin Guinney
Institutions: Sage Bionetworks, Genome Institute of Singapore, Celgene (United States), GNS Healthcare (United States), Stanford Medicine, Stanford University, Moffitt Cancer Center, University Hospital Heidelberg, Institut universitaire du cancer de Toulouse Oncopole, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Erasmus MC Cancer Institute, Multiple Myeloma Research Foundation, Heidelberg University, NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, University of Arkansas for Medical Sciences
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2986190252